RAMAT GAN, Israel, December 1, 2015 /PRNewswire/ --
Molecular Dynamics successfully imaged the first patient on the Valiance X12, its whole-body CZT based digital SPECT/CT prototype at the Chaim Sheba Medical Center in Israel. The Valiance X12 delivers high resolution, low dose, high speed personalized images, based on a unique imaging platform and proprietary imaging algorithms and provides a breakthrough improvement over the currently available general purpose analog SPECT technology.
The scan was completed in the Department of Nuclear Medicine at the Chaim Sheba Medical Center and the clinical study is supervised by Dr. Ronen Goldkorn and Dr. Elinor Goshen. “It is great to have the opportunity to clinically evaluate this unique technology at the Sheba Medical Center. The initial images are very promising,” said Dr. Goshen. “The details shown on the digital SPECT images and their quality highlight the potential of Valiance X12 to revolutionize the field of nuclear medicine.”
Valiance X12’s innovative technology features, including adaptive image acquisition that focuses the detectors on specific organs and simultaneous, multiple isotope, online dynamic imaging, can tailor the imaging process to individual patients and collect more data than conventional SPECT technology does. These advanced features, coupled with superior accuracy at high count rates are designed to enable unprecedented absolute quantification for therapy planning and monitoring. To allow clinicians to take full advantage of this breakthrough, Molecular Dynamics is developing advanced applications to further support patient diagnosis and treatment decisions.
“This is a significant milestone for us,” said Mr. Din Hadass, COO of Molecular Dynamics’s Research and Development subsidiary in Israel. “We are confident that the Sheba study will show how our technology can simultaneously improve image quality and scan time while using a lower patient radiotracer dose.”
Professor Shlomo Ben-Haim, founder of Molecular Dynamics, explained that “by collecting an unprecedented amount of multi-dimensional data from each scan, this innovative technology is paving the way to a new age in nuclear medicine.”
About Molecular Dynamics
Molecular Dynamics, a member of the Hobart Group companies, is developing innovative imaging technologies and advanced clinical applications. The company’s whole body functional imaging system, based on CZT technology, simultaneously improves image quality, scan time and patient dose. When used together with its novel applications, Valiance X12 will enable improved diagnosis and treatment-optimization and monitoring, resulting in more cost-effective treatments and better clinical outcomes. For more information visit http://www.molecular-d.com.
About the Hobart Group
The Hobart Group accelerates ideas and develops and commercializes medical technologies, targeting top healthcare markets with significant unmet needs. Its growing portfolio of companies covers the fields of cardiology, diabetes, oncology, neurology and rehabilitation. Together, Hobart Group companies employ over 200 scientists, engineers, regulatory and business experts across four continents, benefitting from the group’s financial strength, clinical expertise and extensive international market knowledge across Europe, the US and Asia. For more information please visit http://www.hobart-group.com.
Media Inquiries
Mrs. Sharon Alon
Email: Media@molecular-d.com
Tel: +1-347-566-6113
SOURCE Molecular Dynamics
